4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
PolyPeptide Group AG (PPGN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Baar, Switzerland with about 1,460 employees. Its market capitalization is roughly €1 billion. In the fiscal year ended 2025-12-31, PPGN reported €392M in revenue and (€21M) in net income.
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €392M | €339M | €325M | €283M | — |
| Gross Profit | €66M | €39M | €9M | €54M | — |
| Operating Income (EBIT) | €9M | (€6M) | (€34M) | €13M | — |
| Net Income | (€21M) | (€20M) | (€51M) | €8M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | — | — | — | (€10M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | €826M | €757M | €689M | €576M |
| Total Liabilities | €485M | €399M | €308M | €154M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PPGN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms